Medicaments: containing alkaloids or their derivatives, containing norephedrine or its salts, for therapeutic or prophylactic uses, packaged for retail sale

In 2024, medicaments: containing alkaloids or their derivatives, containing norephedrine or its salts, for therapeutic or prophylactic uses, packaged for retail sale trade exhibited strong growth, with global flows reaching $71,108,200 and a three-year compound annual growth rate of +54.1% (five-year: +25.7%). The all-time peak of $71,108,200 was recorded in 2024.

Over the 30-year observation window (1995–2024), 62% of years recorded positive growth, indicating a mildly upward trajectory with periodic contractions. Trend momentum is strengthening (+38.5% acceleration).

The supply side is concentrated (Herfindahl-Hirschman Index 0.345). The three largest exporters — Ireland ($40.6M), Denmark ($7.1M), and France ($7.1M) — collectively dominate supply flows. The leading exporter has grown at +533.2% over the last three years.

On the demand side, importer concentration is concentrated (HHI 0.542). The three largest import markets are Egypt ($52.1M), Philippines ($2.1M), and Estonia ($2.0M). The largest importing market sources from 10 different supplying countries.

The dominant trade corridor is Ireland → Egypt at $40.4M, representing 77.6% of the importer's total demand.

The volatility score for medicaments: containing alkaloids or their derivatives, containing norephedrine or its salts, for therapeutic or prophylactic uses, packaged for retail sale is 11 out of 100, classified as low. Trade flows are relatively stable compared to other HS6 products, suggesting mature supply chains and predictable demand.

For market entrants, strong demand tailwinds create a favourable entry environment. The concentrated supply structure suggests high barriers but also potential opportunity if dominant suppliers face disruption or capacity constraints.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.